When biotech startups take the financial bridge to nowhere

If you noticed that this episode didn't actually go up until late last night, no you didn't.

August 18, 2023 Check out STAT+

Sponsored By

What difference does a day make? Who gets to have gene therapy? And are biotech startups OK? We cover all that and more this week on "The Readout LOUD," STAT's biotech podcast. Our colleague Jason Mast joins us to explain how the approval of a landmark gene therapy for Duchenne muscular dystrophy set in motion a frantic race to get children treated before their 6th birthdays. Then, HSBC Managing Director Jonathan Norris calls in to discuss why so many biotech startups are facing financial bridges to nowhere. Listen Now Subscribe to the podcast to never miss an episode iTunes Spotify SoundCloud Stitcher TuneIn YouTube Visit the archive to see past episodes

---

---

Enjoying The Readout LOUD? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser